Sfoglia per Autore
Trimethylangelicin promotes the functional rescue of F508del CFTR in CF airway cells
2014-01-01 18) FAVIA, M; Mancini, Mt; Bezzerri, V; Guerra, L; Laselva, O; Abbattiscianni, A. C.; Reshkin, Sj; Gambari, R; Cabrini, G; Casavola, V.
TRIMETHYLANGELICIN (TMA) BINDS DIRECTLY TO PURIFIED WILD-TYPE CFTR
2015-01-01 Laselva, O.; Chin, S; Molinski, S.; Ereno, J; Julien, Jp.; Casavola, V.; Bear, C. E.
Correctors of mutant CFTR enhance subcortical cAMP/PKA signaling via ezrin phosphorylation and cytoskeleton organization
2016-01-01 Abbattiscianni, A. C.; Favia, M; Mancini, M. T.; Cardone, R. A.; Guerra, L; Monterisi, S; Castellani, Stefano; Laselva, O; Di Sole, F; Conese, Massimo; Zaccolo, M; Casavola, V.
The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain
2016-01-01 Laselva, O.; Molinski, S.; Casavola, V.; Bear, C. E.
STUDYING THE DISTINCT SENSITIVITIES OF CFTR MODULATORS USING ZEBRAFISH-CFTR
2017-01-01 Laselva, O.; Bagnat, M.; Bear, C. E.
ORKAMBI/amplifier co-therapy rescues a rare CFTR mutation in gene-edited cells and patient tissue
2017-01-01 Molinski, S.; Ahmadi, S.; Kulleperuma, K.; Ip, W.; Ouyang, H.; Villella, A.; Miller, J. P.; Lee, P. S.; Kulleperuma, K.; Du, K; DI PAOLA, M.; Eckford, P.; Laselva, O.; Huan, L. J.; Wellhauser, L; Li, E.; Ray, P. N.; Moraes, T. J. GONSKA T.; Ratjen, F; Bear, C. E.
Molecular mechanism of action of Trimethylangelicin derivatives as CFTR modulators
2018-01-01 Laselva, O.; Marzaro, G.; Vaccarin, C.; Lampronti, I.; Tamanini, A.; Lippi, G.; Gambari, R.; Cabrini, G.; Bear, C. E.; Chilin, A.; Dechecchi, M. C.
HUMAN IPSCS AND NASAL CELL MODELS FOR CFTR THERATYPING
2018-01-01 Bear, C. E.; Laselva, O.; Gonska, T.; Moraes, T. J.; Eckford, P. D.; Ratjen, F
MODULATION OF CFTR BY ITS PHOSPHORYLATION AND INTERACTION WITH SMALL MOLECULES
2018-01-01 Bear, C. E.; Hung, M.; Chin, S.; Laselva, O.; Pasyk, S.; Ahmadi, S.; Viirre, R.; Young, R.
MODELING CYSTIC FIBROSIS DISEASE AND THERAPIES IN PATIENT DERIVED TISSUES
2018-01-01 Xia, S.; Laselva, O.; DI PAOLA, M.; Bartlett, C.; Gonska, T.; Jones, N. L.; Bear, C. E.
Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site
2018-01-01 Molinski, S.; Shahani, V.; Subramanian, A.; Mackinnon, S.; Woollard, G.; Laforet, M.; Laselva, O.; Morayniss, L.; Bear, C. E.; Windemuth, A
Correctors of the major Cystic Fibrosis mutant interact through membrane spanning domains
2018-01-01 Laselva, O.; Molinski, S.; Casavola, V.; Bear, C. E.
ASSESSING THE NEED FOR CORRECTOR COMBINATIONS FOR MISFOLDED CF VARIANTS OTHER THAN F508DEL
2018-01-01 Laselva, O.; Bartlett, C.; Popa, A.; Du, K.; Szarics, I; Ouyang, H.; Moraes, T. J.; Gonska, T.; Bear, C. E.
Activity of Lumacaftor is not conserved in zebrafish Cftr bearing the major Cystic Fibrosis-causing mutation
2019-01-01 Laselva, O.; Erwood, S.; Du, K.; Ivakine, Z.; Bear, C. E.
AN ADENOVIRAL VECTOR EXPRESSING CFTR CAN BE USED TO BENCHMARK CFTR MODULATOR RESPONSES IN PATIENT-DERIVED NASAL EPITHELIAL CELLS
2019-01-01 Ouyang, H.; Cao, H.; Bartlett, C.; Laselva, O.; Gunawardena, T.; Duan, C.; Avolio, J.; Bear, C. E.; Gonska, T.; Hu, J.; MORAES T., J
D1152H MUTATION SHOWS A BICARBONATE BUT NOT A CHLORIDE DEFECT IN PRIMARY NASAL EPITHELIAL CELLS
2019-01-01 Laselva, O.; Moraes, T. J.; He, G.; Barlett, C.; Szaric, S. OUYANG.; Strug, L.; Bear, C. E.; Gonska, T
TOWARDS THE DETERMINATION OF THE BINDING SITE OF IVACAFTOR ON CFTR THROUGH USE OF PHOTOAFFINITY LABELING PROBES
2019-01-01 Hamilton, C.; Laselva, O.; Qureshi, Z.; Hung, M.; Bear, C. E.; Young, R. N.
Orkambi mediated rescue of mucociliary clearance in CF primary respiratory cultures is enhanced by arginine uptake, arginase inhibition and promotion of nitric oxide signalling to the CFTR channel
2019-01-01 Wu, Y-S.; Jiang, J.; Ahmadi, S.; Lew, A.; Laselva, O.; Xia, S.; Bartlett, C.; Ip, W.; Wellhauser, L.; Ouyang, H.; Gonska, T.; Moraes, T. J.; Bear, C. E.
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action
2019-01-01 Laselva, O.; Eckford, P. D. W.; Bartlett, C.; Ouyang, H.; Guanawardena, T. N. A.; Gonska, T.; Moraes, T. J.; Bear, C. E.
Cholesterol interaction directly enhances intrinsic activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
2019-01-01 Chin, S.; Ramjeesingh, M.; Hung, M.; ERENO-OREBA, J.; Cui, H.; Laselva, O.; Julien, J. -P.; Bear, C. E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Trimethylangelicin promotes the functional rescue of F508del CFTR in CF airway cells | 1-gen-2014 | 18) FAVIA, M; Mancini, Mt; Bezzerri, V; Guerra, L; Laselva, O; Abbattiscianni, A. C.; Reshkin, Sj; Gambari, R; Cabrini, G; Casavola, V. | |
| TRIMETHYLANGELICIN (TMA) BINDS DIRECTLY TO PURIFIED WILD-TYPE CFTR | 1-gen-2015 | Laselva, O.; Chin, S; Molinski, S.; Ereno, J; Julien, Jp.; Casavola, V.; Bear, C. E. | |
| Correctors of mutant CFTR enhance subcortical cAMP/PKA signaling via ezrin phosphorylation and cytoskeleton organization | 1-gen-2016 | Abbattiscianni, A. C.; Favia, M; Mancini, M. T.; Cardone, R. A.; Guerra, L; Monterisi, S; Castellani, Stefano; Laselva, O; Di Sole, F; Conese, Massimo; Zaccolo, M; Casavola, V. | |
| The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain | 1-gen-2016 | Laselva, O.; Molinski, S.; Casavola, V.; Bear, C. E. | |
| STUDYING THE DISTINCT SENSITIVITIES OF CFTR MODULATORS USING ZEBRAFISH-CFTR | 1-gen-2017 | Laselva, O.; Bagnat, M.; Bear, C. E. | |
| ORKAMBI/amplifier co-therapy rescues a rare CFTR mutation in gene-edited cells and patient tissue | 1-gen-2017 | Molinski, S.; Ahmadi, S.; Kulleperuma, K.; Ip, W.; Ouyang, H.; Villella, A.; Miller, J. P.; Lee, P. S.; Kulleperuma, K.; Du, K; DI PAOLA, M.; Eckford, P.; Laselva, O.; Huan, L. J.; Wellhauser, L; Li, E.; Ray, P. N.; Moraes, T. J. GONSKA T.; Ratjen, F; Bear, C. E. | |
| Molecular mechanism of action of Trimethylangelicin derivatives as CFTR modulators | 1-gen-2018 | Laselva, O.; Marzaro, G.; Vaccarin, C.; Lampronti, I.; Tamanini, A.; Lippi, G.; Gambari, R.; Cabrini, G.; Bear, C. E.; Chilin, A.; Dechecchi, M. C. | |
| HUMAN IPSCS AND NASAL CELL MODELS FOR CFTR THERATYPING | 1-gen-2018 | Bear, C. E.; Laselva, O.; Gonska, T.; Moraes, T. J.; Eckford, P. D.; Ratjen, F | |
| MODULATION OF CFTR BY ITS PHOSPHORYLATION AND INTERACTION WITH SMALL MOLECULES | 1-gen-2018 | Bear, C. E.; Hung, M.; Chin, S.; Laselva, O.; Pasyk, S.; Ahmadi, S.; Viirre, R.; Young, R. | |
| MODELING CYSTIC FIBROSIS DISEASE AND THERAPIES IN PATIENT DERIVED TISSUES | 1-gen-2018 | Xia, S.; Laselva, O.; DI PAOLA, M.; Bartlett, C.; Gonska, T.; Jones, N. L.; Bear, C. E. | |
| Comprehensive mapping of Cystic Fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site | 1-gen-2018 | Molinski, S.; Shahani, V.; Subramanian, A.; Mackinnon, S.; Woollard, G.; Laforet, M.; Laselva, O.; Morayniss, L.; Bear, C. E.; Windemuth, A | |
| Correctors of the major Cystic Fibrosis mutant interact through membrane spanning domains | 1-gen-2018 | Laselva, O.; Molinski, S.; Casavola, V.; Bear, C. E. | |
| ASSESSING THE NEED FOR CORRECTOR COMBINATIONS FOR MISFOLDED CF VARIANTS OTHER THAN F508DEL | 1-gen-2018 | Laselva, O.; Bartlett, C.; Popa, A.; Du, K.; Szarics, I; Ouyang, H.; Moraes, T. J.; Gonska, T.; Bear, C. E. | |
| Activity of Lumacaftor is not conserved in zebrafish Cftr bearing the major Cystic Fibrosis-causing mutation | 1-gen-2019 | Laselva, O.; Erwood, S.; Du, K.; Ivakine, Z.; Bear, C. E. | |
| AN ADENOVIRAL VECTOR EXPRESSING CFTR CAN BE USED TO BENCHMARK CFTR MODULATOR RESPONSES IN PATIENT-DERIVED NASAL EPITHELIAL CELLS | 1-gen-2019 | Ouyang, H.; Cao, H.; Bartlett, C.; Laselva, O.; Gunawardena, T.; Duan, C.; Avolio, J.; Bear, C. E.; Gonska, T.; Hu, J.; MORAES T., J | |
| D1152H MUTATION SHOWS A BICARBONATE BUT NOT A CHLORIDE DEFECT IN PRIMARY NASAL EPITHELIAL CELLS | 1-gen-2019 | Laselva, O.; Moraes, T. J.; He, G.; Barlett, C.; Szaric, S. OUYANG.; Strug, L.; Bear, C. E.; Gonska, T | |
| TOWARDS THE DETERMINATION OF THE BINDING SITE OF IVACAFTOR ON CFTR THROUGH USE OF PHOTOAFFINITY LABELING PROBES | 1-gen-2019 | Hamilton, C.; Laselva, O.; Qureshi, Z.; Hung, M.; Bear, C. E.; Young, R. N. | |
| Orkambi mediated rescue of mucociliary clearance in CF primary respiratory cultures is enhanced by arginine uptake, arginase inhibition and promotion of nitric oxide signalling to the CFTR channel | 1-gen-2019 | Wu, Y-S.; Jiang, J.; Ahmadi, S.; Lew, A.; Laselva, O.; Xia, S.; Bartlett, C.; Ip, W.; Wellhauser, L.; Ouyang, H.; Gonska, T.; Moraes, T. J.; Bear, C. E. | |
| Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action | 1-gen-2019 | Laselva, O.; Eckford, P. D. W.; Bartlett, C.; Ouyang, H.; Guanawardena, T. N. A.; Gonska, T.; Moraes, T. J.; Bear, C. E. | |
| Cholesterol interaction directly enhances intrinsic activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) | 1-gen-2019 | Chin, S.; Ramjeesingh, M.; Hung, M.; ERENO-OREBA, J.; Cui, H.; Laselva, O.; Julien, J. -P.; Bear, C. E. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile